2021 Year in Review – Securities Litigation Against Life Sciences Companies

March 8, 2022


Over the past several years, there has been a substantial increase in the number of securities class actions filed against publicly-traded life sciences, pharmaceutical, medical device, biotech and healthcare product and service companies. In 2021 the overall number of cases across all industries declined substantially - but life sciences companies once again had by far the greatest number of securities class action filings in 2021 as compared to other sectors.

In this webinar, we will discuss the data and trends for securities litigation case filings, decisions and settlements, and some of the more significant and interesting decisions of 2021. We will provide in-depth analysis of the potential implications of these decisions and discuss practical steps you can take to make informed choices related to your business, including your public disclosures.